Shopping Cart 0
Cart Subtotal
USD 0

Karyopharm Therapeutics Inc (KPTI) - Pharmaceuticals & Healthcare - Deals and Alliances Profile

Restricted to one authorized user; Open on 1 PC/ mobile / Tablet only.
Print Option: Yes
Copy Option: No
Deliverable Format : PDF Via Email

Single User License
USD 250

Restricted to one authorized user; Open on 1 PC/ mobile / Tablet only.
Print Option: Yes
Copy Option: No
Deliverable Format : PDF Via Email

Site License
USD 500

Multiple Users within the Company/ Enterprise
Print Option: Yes
Copy Option: Yes
Deliverable Format : Excel, PDF Via Email

Corporate User License
USD 750
  • Details
  • Table Of Content
  • Licence Rights
  • Section Purchase
  • Products and Companies

Details

Summary

Karyopharm Therapeutics Inc (Karyopharm Therapeutics) is a clinical-stage pharmaceutical company that discovers and develops novel drugs for the treatment of cancer and other diseases. The company develops small molecule selective inhibitor of nuclear export compounds that inhibit the nuclear export protein XPO1. Its pipeline drug candidates include oral selinexor, oral verdinexor, oral KPT-8602 and oral KPT-9274. Karyopharm Therapeutics drug candidates are indicated for the treatment of various hematological and solid tumor malignancies including multiple myeloma, acute myeloid leukemia, diffuse large B-cell lymphoma, liposarcoma, glioblastoma and gynecological malignancies. The company operates across the US and Germany. Karyopharm Therapeutics is headquartered in Newton, Massachusetts, the US.

Karyopharm Therapeutics Inc (KPTI)-Pharmaceuticals & Healthcare-Deals and Alliances Profile provides you comprehensive data and trend analysis of the company's Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.

Scope

- Financial Deals-Analysis of the company's financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.

- Deals by Year-Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.

- Deals by Type-Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.

- Deals by Region-Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.

- Deals by Sub-sector-Chart and table showing information on the number of deals and value reported by the company, by sub-sector.

- Major Deals-Information on the company's major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company's (major public companies) key financial metrics and ratios.

- Business Description-A brief description of the company's operations.

- Key Employees-A list of the key executives of the company.

- Important Locations and Subsidiaries-A list and contact details of key centers of operation and subsidiaries of the company.

- Key Competitors-A list of the key competitors of the company.

- Key Recent Developments-A brief on recent news about the company.

Reasons to Buy

Get detailed information on the company's financial deals that enable you to understand the company's expansion/divestiture and fund requirements

- The profile enables you to analyze the company's financial deals by region, by year, by business segments and by type, for a five year period.

Understand the company's business segments' expansion / divestiture strategy

- The profile presents deals from the company's core business segments' perspective to help you understand its corporate strategy.

Access elaborate information on the company's recent financial deals that enable you to understand the key deals which have shaped the company

- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company's key financial metrics and ratios.

Equip yourself with detailed information about the company's operations to identify potential customers and suppliers.

- The profile analyzes the company's business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company

- Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research

- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.

READ MORE

Table Of Content

Scope

Table of Contents

Table of Contents 3

List of Tables 6

List of Figures 6

Karyopharm Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 7

Karyopharm Therapeutics Inc, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 8

Karyopharm Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 9

Karyopharm Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 10

Karyopharm Therapeutics Inc, Medical Devices Deals, 2012 to YTD 2018 11

Karyopharm Therapeutics Inc, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 12

Karyopharm Therapeutics Inc, Pharmaceuticals & Healthcare, Deal Details 13

Venture Financing 13

Karyopharm Therapeutics Raises USD 67.2 Million In Series B Venture Financing 13

Partnerships 15

Veristat Enters into Agreement with Karyopharm Therapeutics 15

Licensing Agreements 16

Antengene Enters into Licensing Agreement with Karyopharm Therapeutics 16

ONO Pharma Enters into Licensing Agreement with Karyopharm Therapeutics 17

Equity Offering 18

Karyopharm Therapeutics to Raise up to USD75 Million in Public Offering of Shares 18

Karyopharm Therapeutics Raises USD155.2 Million in Public Offering of Shares 20

Karyopharm Therapeutics Files Registration Statement for Public Offering of Securities for up to USD250 Million 22

Karyopharm Therapeutics to Raise up to USD75 million in Public Offering of Shares 23

Karyopharm Therapeutics Raises USD40 million in Public Offering of Shares 24

Karyopharm Therapeutics to Raise up to USD50 Million in Public Offering of Shares 26

Karyopharm Therapeutics Raises USD97.4 Million in Public Offering of Shares 28

Karyopharm Therapeutics Raises USD120.88 Million in Public Offering of Shares 30

Karyopharm Therapeutics Completes Underwriters Exercise Of Full Over-Allotment Option Of IPO For USD 125 Million 32

Debt Offering 34

Karyopharm Therapeutics Exercise of Over-Allotment Option of Private Placement of Convertible Senior Notes Due 2025 for USD172.5 Million 34

Asset Transactions 35

Biogen Acquires Rights to KPT-350 from Karyopharm Therapeutics 35

Karyopharm Therapeutics Inc-Key Competitors 36

Karyopharm Therapeutics Inc-Key Employees 37

Karyopharm Therapeutics Inc-Locations And Subsidiaries 38

Head Office 38

Other Locations & Subsidiaries 38

Recent Developments 39

Financial Announcements 39

Aug 07, 2018: Karyopharm Reports Second Quarter 2018 Financial Results and Highlights Recent Progress 39

May 10, 2018: Karyopharm Reports First Quarter 2018 Financial Results and Highlights Recent Progress 42

Mar 15, 2018: Karyopharm Reports Fourth Quarter and Full Year 2017 Financial Results and Highlights Recent Progress 45

Nov 02, 2017: Karyopharm Reports Third Quarter 2017 Financial Results and Highlights Recent Progress 48

Aug 08, 2017: Karyopharm Reports Second Quarter 2017 Financial Results and Highlights Recent Progress 51

May 04, 2017: Karyopharm Reports First Quarter 2017 Financial Results and Highlights Recent Progress 52

Corporate Communications 55

Oct 26, 2018: Karyopharm Therapeutics announces management change 55

Sep 12, 2017: Karyopharm Appoints Michael Falvey as Chief Financial Officer, Adds New Clinical Strategy and Human Resources Executives and Reports Inducement Grant Under NASDAQ Listing Rule 5635(c)(4) 56

Apr 03, 2017: Karyopharm Announces Management Change 58

Product News 59

12/10/2017: Karyopharm Presents Positive Phase 1/2 Eltanexor Data at the American Society of Hematology 2017 Annual Meeting 59

12/10/2017: Karyopharm Presents Positive Selinexor Data from the Phase 1b/2 STOMP Study at the American Society of Hematology 2017 Annual Meeting 61

09/20/2017: Karyopharm Announces Successful Outcome from Phase 2 Portion of Phase 2/3 SEAL Study Evaluating Selinexor in Patients with Previously Treated Advanced Dedifferentiated Liposarcoma 64

06/25/2018: Karyopharm Appoints Anand Varadan as Chief Commercial Officer and Reports Inducement Grant Under NASDAQ Listing Rule 5635(c)(4) 66

06/15/2018: Karyopharm Presents Updated Selinexor Phase 1b/2 STOMP Myeloma Data from Multiple Combinations at the European Hematology Association 2018 Annual Meeting 68

06/01/2018: Karyopharm to Present Selinexor Phase 2/3 SEAL Data at the American Society of Clinical Oncology 2018 Annual Meeting 71

Product Approvals 74

Jul 18, 2018: Karyopharm Initiates Rolling Submission of New Drug Application to U.S. Food and Drug Administration for Selinexor as a Treatment for Patients with Penta-Refractory Multiple Myeloma 74

Apr 10, 2018: Karyopharms Selinexor Receives Fast Track Designation from FDA for the Treatment of Patients with Penta-Refractory Multiple Myeloma 76

Clinical Trials 77

May 17, 2018: Karyopharm to Present Selinexor Phase 1b/2 STOMP Data at the European Hematology Association 2018 Annual Meeting 77

May 16, 2018: Karyopharm to Present Selinexor Phase 2 SEAL Data at the American Society of Clinical Oncology 2018 Annual Meeting 79

Apr 30, 2018: Karyopharm Announces Positive Top-Line Data from Phase 2b STORM Study Evaluating Selinexor in Patients with Penta-Refractory Multiple Myeloma 81

Mar 19, 2018: Karyopharm to Present Preclinical Data On Eltanexor at the American Association for Cancer Research 2018 Annual Meeting 83

Mar 19, 2018: Karyopharm to Present Preclinical Data on KPT-9274 at the American Association for Cancer Research 2018 Annual Meeting 84

Mar 19, 2018: Karyopharm to Present Preclinical Data on Selinexor at the American Association for Cancer Research 2018 Annual Meeting 85

Jan 31, 2018: Multiple Myeloma Research Foundation (MMRF) and Karyopharm Collaboration Drives the Advancement of Selinexor, a First-In-Class, Next-Generation Myeloma Therapy 87

Dec 10, 2017: Karyopharm Presents Data On Selinexor (KPT-330) At The American Society of Hematology 2017 Annual Meeting 88

Nov 01, 2017: Karyopharm to Present Phase 1b/2 STOMP Clinical Data at the American Society of Hematology 2017 Annual Meeting 89

Sep 08, 2017: Karyopharm Announces Presentation of KPT-9274 Clinical Data at European Society of Medical Oncology 2017 Annual Meeting 92

Sep 08, 2017: Karyopharm Announces Presentation of Selinexor Clinical Data at European Society of Medical Oncology 2017 Annual Meeting 93

Aug 30, 2017: Karyopharm Announces the Presentation of KPT-9274 Clinical Data at the European Society of Medical Oncology 2017 Annual Meeting 94

Aug 30, 2017: Karyopharm Announces the Presentation of Selinexor Clinical Data at the European Society of Medical Oncology 2017 Annual Meeting 95

Aug 08, 2017: Karyopharm Provides Update on Selinexor (KPT-330) 96

Jun 23, 2017: Karyopharm Reports Updated Phase 2b SADAL Data for Selinexor in Diffuse Large B-Cell Lymphoma at the 2017 European Hematology Association Annual Meeting 98

Jun 07, 2017: Karyopharm Doses First Patient in Pivotal Phase 3 BOSTON Study Evaluating Selinexor in Patients with Relapsed/Refractory Multiple Myeloma 100

May 18, 2017: Karyopharm's Phase 2b SADAL Data Evaluating Selinexor in Diffuse Large B-Cell Lymphoma Selected for Oral Presentation at the 2017 European Hematology Association Annual Meeting 101

Apr 04, 2017: Karyopharm Reports Interim Phase 2b SADAL Data at the 2017 American Association for Cancer Research Annual Meeting 102

Appendix 104

Methodology 104

About GlobalData 104

Contact Us 104

Disclaimer 104


List Of Figure

List of Figures

Karyopharm Therapeutics Inc, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 2

Karyopharm Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 2

Karyopharm Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 2

Karyopharm Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 2

Karyopharm Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 7

Karyopharm Therapeutics Inc, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 8

Karyopharm Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 9

Karyopharm Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 10

Karyopharm Therapeutics Inc, Medical Devices Deals, 2012 to YTD 2018 11


List Of Table

List of Tables

Karyopharm Therapeutics Inc, Pharmaceuticals & Healthcare, Key Facts, 2017 2

Karyopharm Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 7

Karyopharm Therapeutics Inc, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 8

Karyopharm Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 9

Karyopharm Therapeutics Inc, Deals By Therapy Area, 2012 to YTD 2018 10

Karyopharm Therapeutics Inc, Medical Devices Deals, 2012 to YTD 2018 11

Karyopharm Therapeutics Inc, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 12

Karyopharm Therapeutics Raises USD 67.2 Million In Series B Venture Financing 13

Veristat Enters into Agreement with Karyopharm Therapeutics 15

Antengene Enters into Licensing Agreement with Karyopharm Therapeutics 16

ONO Pharma Enters into Licensing Agreement with Karyopharm Therapeutics 17

Karyopharm Therapeutics to Raise up to USD75 Million in Public Offering of Shares 18

Karyopharm Therapeutics Raises USD155.2 Million in Public Offering of Shares 20

Karyopharm Therapeutics Files Registration Statement for Public Offering of Securities for up to USD250 Million 22

Karyopharm Therapeutics to Raise up to USD75 million in Public Offering of Shares 23

Karyopharm Therapeutics Raises USD40 million in Public Offering of Shares 24

Karyopharm Therapeutics to Raise up to USD50 Million in Public Offering of Shares 26

Karyopharm Therapeutics Raises USD97.4 Million in Public Offering of Shares 28

Karyopharm Therapeutics Raises USD120.88 Million in Public Offering of Shares 30

Karyopharm Therapeutics Completes Underwriters Exercise Of Full Over-Allotment Option Of IPO For USD 125 Million 32

Karyopharm Therapeutics Exercise of Over-Allotment Option of Private Placement of Convertible Senior Notes Due 2025 for USD172.5 Million 34

Biogen Acquires Rights to KPT-350 from Karyopharm Therapeutics 35

Karyopharm Therapeutics Inc, Key Competitors 36

Karyopharm Therapeutics Inc, Key Employees 37

Karyopharm Therapeutics Inc, Subsidiaries 38

Licence Rights

Single User License:
Report can be used by individual purchaser only

Site License:
Report can be shared by unlimited users within one corporate location, e.g. a regional office

Corporate User License: 
Report can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company

Section Purchase

To know more information on Purchase by Section, please send a mail to support@kenresearch.com

Products and Companies

Products

Karyopharm Therapeutics Inc, Deal Analysis, Mergers, Acquisitions, Asset Purchases, Asset Divestitures, Company Divestitures, Equity Offerings, Capital Raising, Debt Offerings, IPOs, Initial Public Offering, Private Placement, Private Investment In Public Equities, Secondary Offerings, Follow-On Offerings, Debt Private Placement, Public Debt Placement, Partnerships, Joint Venture, Licensing Agreements, Co-Marketing Agreements, Upfront Payment, Milestone Payment, Phases, Clinical Trials, Private Equity, Venture Capital, PE,VC, Asset Finance, Project Finance, Tax Equity Financing, Bond Financing, Lease Financing, New Build Financing, Deal Analysis By Market/sector, Deal Analysis By Geography, Deal Analysis By Deal Types, Key Employees, Locations And Subsidiaries, Competitors, Recent News, Company Overview, Key Facts, Deals By Year, Deal Details, Recent Developments, Significant Developments.